



Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.

6 January 2026

**Proteome Sciences plc
("Proteome Sciences" or the "Company")**

Two further substantial contracts for Proteome Sciences

Proteome Sciences (AIM:PRM), is pleased to announce that following the Company's announcement dated 8 December 2025, the Company has secured two further substantial Good Clinical Laboratory Practice ("GCLP") contracts. The contracts have a combined value in excess of \$1.5m. Trial samples are expected to be shipped in late Q1 this year, with the major part of the contracts completed in 2026.

Commenting on the contracts, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:

"We continue to experience strong interest in GCLP work from major biopharma clients in both the US and Europe and expect further orders to materialise in due course. These new contracts together with contracts previously secured provide a strong order book supporting our business through 2026."

- Ends -

For further information:

Proteome Sciences plc

Dr. Ian Pike, Chief Scientific Officer

Richard Dennis, Chief Commercial Officer

Tel: +44 (0)20 7043 2116

SP Angel Corporate Finance LLP (Nominated Adviser & Broker)

David Hignell/Richard Morrisom/Josh Ray (Corporate Finance)

Vadim Alexandre (Corporate Broking)

Tel: +44 (0) 20 3470 0470

About Proteome Sciences plc. (www.proteomics.com)

Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum

analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.